Comparative cardiovascular effects of thiazolidinediones

Comparative cardiovascular effects of thiazolidinediones

Article Type: Reviews of effectiveness From: Clinical Governance: An International Journal, Volume 16, Issue 3

Loke, Y.K., Kwok, C.S., Singh, S.Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studiesBMJ2011Vol. 342d1309

This review concluded that in patients with type 2 diabetes, rosiglitazone was associated with significantly higher odds of congestive heart failure,myocardial infarction, and death, than pioglitazone, in real-world settings. This was a generally well-conducted review. The authors acknowledged the methodological limitations of the evidence available and the conclusions are likely to be reliable.